

WS1: Demonstration study of rapid large scale HCV DAA therapy to PWID in Tayside (intervention site)

- ☐ Can rapid large-scale HCV DAA therapy be delivered to PWID in the community?
- ☐ Are cure (SVR) rates comparable to other real-world examples?
- ☐ What is the rate of HCV re-infection following treatment and cure?

WS1 recruits patients for WS3

WS3: Qualitative study of the barriers and facilitators to scaling up HCV DAA therapy to PWID

- ☐ What are the system-, provider- and patient-level barriers and facilitators to scaling up HCV DAA therapy to PWID?
- ☐ What are the collateral effects of HCV DAA therapy on health risk behaviours of PWID, their engagement with services and perceptions of 'recovery'?

WS1 provides a template for scaling up therapy in WS5

WS3 generates logic model and manual on how best to scale-up therapy in WS5

WS5: Evaluation of HCV Treatment as Prevention in England

- ☐ Can we conduct a large-scale evaluation to provide definitive evidence for patients, clinicians and policy makers?

WS4 provides model estimates and methods for design of evaluation in WS5

WS2 provides outcome data for evaluation in WS5

WS4: Modelling the intervention effect and cost-effectiveness of scaling up HCV DAA therapy to PWID

- ☐ What is the effect of the intervention (in WS1) on chronic HCV prevalence among PWID?
- ☐ What is the contribution of HCV treatment and other primary prevention interventions to the intervention effect?
- ☐ What is the cost-effectiveness of HCV Treatment as Prevention using real-world data?

WS2 provides data for impact and economic modelling in WS4

WS2: Enhancing Public Health Surveillance to monitor HCV, behaviours and service utilisation among PWID in the intervention and control sites across the UK

- ☐ What are the trends in chronic HCV prevalence & incidence among PWID in intervention and control sites pre and post the demonstration study (in WS1)?
- ☐ Can we develop methods to estimate the number of PWID and chronic HCV PWID?
- ☐ Can we determine if DAA therapy leads to improved health risk behaviours and uptake of drug services?

WS1 provides data for impact and economic modelling in WS4